These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 36002369)

  • 21. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS
    Ricciuti B; Alessi JV; Elkrief A; Wang X; Cortellini A; Li YY; Vaz VR; Gupta H; Pecci F; Barrichello A; Lamberti G; Nguyen T; Lindsay J; Sharma B; Felt K; Rodig SJ; Nishino M; Sholl LM; Barbie DA; Negrao MV; Zhang J; Cherniack AD; Heymach JV; Meyerson M; Ambrogio C; Jänne PA; Arbour KC; Pinato DJ; Skoulidis F; Schoenfeld AJ; Awad MM; Luo J
    Ann Oncol; 2022 Oct; 33(10):1029-1040. PubMed ID: 35872166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.
    Landre T; Justeau G; Assié JB; Chouahnia K; Davoine C; Taleb C; Chouaïd C; Duchemann B
    Cancer Immunol Immunother; 2022 Mar; 71(3):719-726. PubMed ID: 34378081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy.
    Veccia A; Dipasquale M; Kinspergher S; Monteverdi S; Girlando S; Barbareschi M; Caffo O
    Target Oncol; 2023 Jan; 18(1):129-138. PubMed ID: 36482151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
    Aredo JV; Padda SK; Kunder CA; Han SS; Neal JW; Shrager JB; Wakelee HA
    Lung Cancer; 2019 Jul; 133():144-150. PubMed ID: 31200821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
    Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
    Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
    Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
    Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
    Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
    Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.
    Liu Y; Gao Y; Wang Y; Zhao C; Zhang Z; Li B; Zhang T
    BMC Cancer; 2022 Nov; 22(1):1175. PubMed ID: 36376839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kirsten rat sarcoma viral oncogene homolog G12C mutant advanced non-small-cell lung cancer treated with MEK1/2 inhibitor trametinib: a case report.
    Jiang Y; Liu X; Lv DL; Zhao XL
    Anticancer Drugs; 2022 Jan; 33(1):e752-e755. PubMed ID: 34387588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
    Serna-Blasco R; Sánchez-Herrero E; Sanz-Moreno S; Rodriguez-Festa A; García-Veros E; Casarrubios M; Sierra-Rodero B; Laza-Briviesca R; Cruz-Bermúdez A; Mielgo-Rubio X; Sánchez-Hernández A; Uribelarrea EA; Calvo V; Romero A; Provencio M
    ESMO Open; 2021 Oct; 6(5):100279. PubMed ID: 34607284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
    Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
    BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy.
    Gu G; Liu C; Zhu X; Yang Y; Song S; Zhao Y; Sun G
    J Cancer Res Clin Oncol; 2024 Sep; 150(9):413. PubMed ID: 39244518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
    Cui W; Franchini F; Alexander M; Officer A; Wong HL; IJzerman M; Desai J; Solomon BJ
    Lung Cancer; 2020 Aug; 146():310-317. PubMed ID: 32619782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent.
    Batra U; Nathany S; Sharma M; Bp A; Jose JT; Singh H; Mattoo S; Mehta A
    Cancer Med; 2023 Feb; 12(3):2869-2874. PubMed ID: 36069080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.